search
Back to results

Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients

Primary Purpose

Infertility

Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
Sponsored by
Kasr El Aini Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. All patients have PCOS.
  2. All patients received CC 100 mg/day for 5 days starting from day 5 with successful ovulation as documented by folliculometry and midluteal serum progesterone with no pregnancy achieved.
  3. All patients have patent fallopian tubes by Hysterosalpingography.
  4. Their husbands have normal semen analysis according to the modified criteria of WHO.
  5. All patients have normal serum prolactin and thyroid profile.
  6. Any patient having vaginitis was treated before starting induction.

Exclusion Criteria:

  1. Other causes of infertility than anovulation.
  2. Diabetes or other endocrinological disorders.
  3. Age > 40 years.
  4. Smoking.
  5. Alcohol use.
  6. Presence of ovarian cyst >2cm on the second day of the cycle.
  7. Patients who have received gonadotrophins in the preceeding 6 months.
  8. Patients who have done unilateral or bilateral ovarian drilling.
  9. Allergy to PE, NO donors or NAC

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Arm Label

    Phytoestrogen

    Isosorbid mononitrate

    N-Acetyl cysteine

    Arm Description

    Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.

    Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.

    Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.

    Outcomes

    Primary Outcome Measures

    clinical pregnancy rate

    Secondary Outcome Measures

    Full Information

    First Posted
    July 7, 2015
    Last Updated
    July 10, 2015
    Sponsor
    Kasr El Aini Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02493933
    Brief Title
    Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients
    Official Title
    Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2015
    Overall Recruitment Status
    Unknown status
    Study Start Date
    July 2015 (undefined)
    Primary Completion Date
    December 2015 (Anticipated)
    Study Completion Date
    December 2015 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Kasr El Aini Hospital

    4. Oversight

    5. Study Description

    Brief Summary
    To evaluate the effect of oral Phytoestrogen or Isosorbid mononitrate or N-acetyl cysteine as an adjuvant to clomiphene citrate on induction of ovulation and pregnancy outcomes in patients with PCOS. In this three-arm open RCT, 240 PCOS infertile women were randomly divided to 3 groups for induction of ovulation. Group A, [PE group, n= 80] patients received CC 100mg/d plus oral Phytoestrogen120 mg/ day and patients in Group B, [ISMN group, n=80] received CC 100 mg/d plus 20 mg Isosorbid mononitrate and Group C, [NAC group, n=80] patients received CC 100 mg/d plus NAC 1200 mg/day.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Infertility

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    240 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Phytoestrogen
    Arm Type
    Active Comparator
    Arm Description
    Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
    Arm Title
    Isosorbid mononitrate
    Arm Type
    Active Comparator
    Arm Description
    Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
    Arm Title
    N-Acetyl cysteine
    Arm Type
    Active Comparator
    Arm Description
    Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
    Intervention Type
    Drug
    Intervention Name(s)
    Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
    Primary Outcome Measure Information:
    Title
    clinical pregnancy rate
    Time Frame
    6 months

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: All patients have PCOS. All patients received CC 100 mg/day for 5 days starting from day 5 with successful ovulation as documented by folliculometry and midluteal serum progesterone with no pregnancy achieved. All patients have patent fallopian tubes by Hysterosalpingography. Their husbands have normal semen analysis according to the modified criteria of WHO. All patients have normal serum prolactin and thyroid profile. Any patient having vaginitis was treated before starting induction. Exclusion Criteria: Other causes of infertility than anovulation. Diabetes or other endocrinological disorders. Age > 40 years. Smoking. Alcohol use. Presence of ovarian cyst >2cm on the second day of the cycle. Patients who have received gonadotrophins in the preceeding 6 months. Patients who have done unilateral or bilateral ovarian drilling. Allergy to PE, NO donors or NAC

    12. IPD Sharing Statement

    Learn more about this trial

    Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients

    We'll reach out to this number within 24 hrs